centene corp on thursday said it agreed to sell a pair of pharmacy businesses for total proceeds of about 28 billion as the healthcare company works to reshape its portfolio centene which last year said it would exit the pharmacybenefitmanagement space said it plans to sell pharmacy solutions organization magellan rx to prime therapeutics llc centene acquired magellan rx in january as part of its acquisition of magellan health inc separately centene said it agreed to sell specialty and rare pharmacy pantherx rare to a consortium of vistria group general atlantic and nautic partners centene said it expects to complete the sale of pantherx in the next two to four months and the sale of magellan rx by the end of the year adding that it would use the majority of the proceeds to buy back stock and the remainder to pare its debt load